Role of Cancer Stem Cells in Malignant Progression of Ductal Carcinoma in Situ.
Role of Cancer Stem Cells in Malignant Progression of Ductal Carcinoma in Situ.
批准号:
8079455
负责人:
FARIBA BEHBOD
金额:
$24.15万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-06-01 至 2013-05-31
关键词:
AccountingAddressAmericanBasic ScienceBiologicalBiological AssayBrain NeoplasmsBreastCancer BiologyCancer CenterCancerousCell Adhesion MoleculesCell LineCell SeparationCell surfaceCellsClinicalCoculture TechniquesCollaborationsCommitDataDevelopmentDiagnosisDifferentiation and GrowthDilution TechniquesDiseaseDistant MetastasisDoctor of PhilosophyEGFR geneERBB2 geneEducationEndothelial CellsEnvironmentEpidemiologyEpithelial CellsExhibitsFatty acid glycerol estersFocus GroupsFrequenciesGenerationsGenesGeneticGoalsGrowthHematopoietic stem cellsHeterogeneityHousingHumanImmunocompromised HostIn VitroInvasive LesionK-Series Research Career ProgramsLabelLeadLesionLifeMalignant - descriptorMalignant NeoplasmsMammary NeoplasmsMammary glandMediatingMedicineModelingMolecularMolecular TargetMusNoninfiltrating Intraductal CarcinomaNormal tissue morphologyPalpablePatientsPhenotypePopulationPremalignantPremalignant CellPreventionPropertyRecurrenceResearchResearch DesignRisk AssessmentRoleSamplingSignal TransductionStem cellsSurfaceTechniquesTestingTherapeuticTimeTranslational ResearchTransplantationTumorigenicityWomanXenograft procedurebasecancer cellcancer stem cellcareercollegedisorder later incidence preventionexperienceimprovedin vivoleukemiamalignant breast neoplasmmatrigelmortalitymouse modelnovelnovel strategiespost-doctoral trainingpreventprogenitorprognosticrelating to nervous systemself-renewalstemstem cell biologystem cell nichetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): My specific aims are to examine the role of cancer stem cells and their niche microenvironment in malignant progression of subtypes of human breast premalignancy, ductal carcinoma in situ (DCIS). The objectives are to test whether premalignant cell lines, SUM225, MCF10ATDCIS.com, and subtypes of human DCIS contain distinct cancer stem cell subpopulations which exhibit unique cancer stem cell properties of increased self-renewal potential, quiescence, and tumorigenicity. My strategy is to use fluorescent activated cell sorting (FACS) and known surface markers to isolate stem/progenitor and differentiated subpopulations and to examine their cancer stem cell properties which include, 1) in vitro self-renewal and differentiation potential by standard mammosphere assay and colony formation in Matrigel, respectively, 2) in vivo long term and short term self-renewal by using a novel strategy of xenotransplantation into humanized stroma of mice fat pads, 3) tumorigenicity by growth rate and potential to form invasive lesions, and 4) quiescence by long term label retaining studies. Furthermore, the role of endothelial cells in establishing a cancer stem cell niche microenvironment will be examined by in vitro co-culture and in vivo co-transplantation studies. My rationale is that cancer stem cells and normal tissue stem cells express similar surface markers by which they may be identified and characterized. Once cancer stem cells are identified, efforts will be aimed at defining their unique gene profiles. These studies will provide a basis for discovery of molecular targets for risk assessment, prevention of recurrence, and malignant progression tailored to subtypes of DCIS. My long term career goal is to lead a research group focused towards prevention of human breast cancer malignant progression in a translational research environment. I served as an academic and clinical pharmacologist for seven years before obtaining a Ph.D. and post-doctoral training in basic sciences in cellular signaling and mouse mammary gland stem cell biology. The Career Development Award is an excellent opportunity to gain additional experience in research in human breast cancer in collaboration with the Breast Cancer Center at Baylor College of Medicine. Baylor College of Medicine houses exceptional research centers and facilities and provides an ample opportunity for scientific collaboration, and education.
Relevance: Breast pre-cancer lesions may contain a rare population of cancer stem cells. Cancer stem cells may be unique to different types of pre-cancer lesions and may explain why some patients will experience recurrences or develop invasive cancers while others do not. My goal is to examine the role of cancer stem cells in invasive progression of subtypes of pre-cancer lesions and to develop individualized strategies for risk assessment and prevention of invasive breast cancer.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ.
DOI:
10.1186/bcr2358
发表时间:
2009
期刊:
Breast cancer research : BCR
影响因子:
--
作者:
[Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, Young E, Mukhopadhyay P, Yeh HW, Allred DC, Hu M, Polyak K, Rosen JM, Medina D]
通讯作者:
Medina D
DOI:
10.1002/path.2969
发表时间:
2011-12
期刊:
JOURNAL OF PATHOLOGY
影响因子:
7.3
作者:
[Valdez, Kelli Elizabeth, Fan, Fang, Smith, William, Allred, D. Craig, Medina, Daniel, Behbod, Fariba]
通讯作者:
Behbod, Fariba
DOI:
10.1007/s10911-012-9248-2
发表时间:
2012
期刊:
Journal of mammary gland biology and neoplasia
影响因子:
2.5
作者:
[Behbod,Fariba, Rosen,JeffreyM]
通讯作者:
Rosen,JeffreyM
DOI:
10.2174/138945010792006843
发表时间:
2010-09
期刊:
Current drug targets
影响因子:
3.2
作者:
[Pal A, Valdez KE, Carletti MZ, Behbod F]
通讯作者:
Behbod F
DOI:
10.1007/s10549-012-2220-4
发表时间:
2012-10
期刊:
Breast cancer research and treatment
影响因子:
3.8
作者:
[Li H, Duhachek-Muggy S, Qi Y, Hong Y, Behbod F, Zolkiewska A]
通讯作者:
Zolkiewska A
共 7 条
Identifying the Molecular and Cellular Basis of Invasive Phenotype in Human DCIS
-
批准号:9311984
-
项目类别:
-
资助金额:$57.63万
-
财政年份:2017
-
负责人:FARIBA BEHBOD
-
依托单位:
Elucidating cellular heterogeneity among cancer stem cells by Raman Spectroscopy
-
批准号:8758098
-
项目类别:
-
资助金额:$17.49万
-
财政年份:2014
-
负责人:FARIBA BEHBOD
-
依托单位:
Elucidating cellular heterogeneity among cancer stem cells by Raman Spectroscopy
-
批准号:8916059
-
项目类别:
-
资助金额:$14.51万
-
财政年份:2014
-
负责人:FARIBA BEHBOD
-
依托单位:
Progression of DCIS to invasive breast cancer through CCR2 chemokine signaling
-
批准号:9093752
-
项目类别:
-
资助金额:$41.23万
-
财政年份:2013
-
负责人:FARIBA BEHBOD
-
依托单位:
Progression of DCIS to invasive breast cancer through CCR2 chemokine signaling
-
批准号:8579298
-
项目类别:
-
资助金额:$41.34万
-
财政年份:2013
-
负责人:FARIBA BEHBOD
-
依托单位:
Progression of DCIS to invasive breast cancer through CCR2 chemokine signaling
-
批准号:9297227
-
项目类别:
-
资助金额:$41.35万
-
财政年份:2013
-
负责人:FARIBA BEHBOD
-
依托单位:
Progression of DCIS to invasive breast cancer through CCR2 chemokine signaling
-
批准号:8853250
-
项目类别:
-
资助金额:$41.41万
-
财政年份:2013
-
负责人:FARIBA BEHBOD
-
依托单位:
ROLE OF MIR146B IN SURVIVAL & SELF RENEWAL OF MAMMARY ALVEOLAR PROGENITOR CELLS
-
批准号:8360688
-
项目类别:
-
资助金额:$2.95万
-
财政年份:2011
-
负责人:FARIBA BEHBOD
-
依托单位:
Role of Cancer Stem Cells in Malignant Progression of Ductal Carcinoma in Situ.
-
批准号:7672069
-
项目类别:
-
资助金额:$11.91万
-
财政年份:2007
-
负责人:FARIBA BEHBOD
-
依托单位:
Role of Cancer Stem Cells in Malignant Progression of Ductal Carcinoma in Situ.
-
批准号:7811251
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2007
-
负责人:FARIBA BEHBOD
-
依托单位:
Role of Cancer Stem Cells in Malignant Progression of Ductal Carcinoma in Situ.
-
批准号:7418975
-
项目类别:
-
资助金额:$1.7万
-
财政年份:2007
-
负责人:FARIBA BEHBOD
-
依托单位:
Role of Cancer Stem Cells in Malignant Progression of Ductal Carcinoma in Situ.
-
批准号:7847705
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2007
-
负责人:FARIBA BEHBOD
-
依托单位:
Role of Cancer Stem Cells in Malignant Progression of Ductal Carcinoma in Situ.
-
批准号:7250765
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2007
-
负责人:FARIBA BEHBOD
-
依托单位:
Stem Cells in Normal Mammary Development and Cancer
-
批准号:6737510
-
项目类别:
-
资助金额:$5.65万
-
财政年份:2003
-
负责人:FARIBA BEHBOD
-
依托单位:
Stem Cells in Normal Mammary Development and Cancer
-
批准号:6891946
-
项目类别:
-
资助金额:$5.75万
-
财政年份:2003
-
负责人:FARIBA BEHBOD
-
依托单位:
Stem Cells in Normal Mammary Development and Cancer
-
批准号:6646793
-
项目类别:
-
资助金额:$5.63万
-
财政年份:2003
-
负责人:FARIBA BEHBOD
-
依托单位:
海外基金